FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023241724> ?p ?o ?g. }

• W2023241724 endingPage "164" @default.
• W2023241724 startingPage "148" @default.
• W2023241724 abstract "CA: A Cancer Journal for CliniciansVolume 45, Issue 3 p. 148-164 ArticleFree Access How to use prostate-specific antigen in the early detection orscreening for prostatic carcinoma Michael K. Brawer MD, Michael K. Brawer MD Professor in the Department of Urology at the University of Washington and Chief of the Section of Urology at the Seattle Veteran's Administration Medical CenterSearch for more papers by this author Michael K. Brawer MD, Michael K. Brawer MD Professor in the Department of Urology at the University of Washington and Chief of the Section of Urology at the Seattle Veteran's Administration Medical CenterSearch for more papers by this author First published: May/June 1995 https://doi.org/10.3322/canjclin.45.3.148Citations: 30AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Wingo PA, Tong T, Bolden S: Cancer statistics, 1995. CA Cancer J Clin 1995; 45: 8– 30. 2 Seidman H, Mushinski MH, Gelb SK, Silverberg E: Probabilities of eventually developing or dying of cancer: United States, 1985. CA 1985; 35: 36– 56. 3 Scardino PT, Weaver R, Hudson MA: Early detection of prostate cancer. Human Pathology 1992; 23: 211– 222. 4 Brawer MK, Ellis WJ: Chemoprevention for pro-static carcinoma. Cancer 1994. In Press. 5 Stamey TA, Yang N, Hay AR, et al: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909– 916. 6 Ercole CJ, Lange PH, Mathisen M, et al: Prostate specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol 1987; 138: 1181– 1184. 7 Ferro MA, Barnes I, Roberts JBM, Smith PJB: Tumour markers in prostatic carcinoma: A comparison of prostate-specific antigen with acid phosphatase. Br J Urol 1987; 60: 69– 73. 8 Hudson MA, Bahnson RR, Catalona WJ: Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 1989; 142: 1011– 1017. 9 Sensabaugh GF, Crim D: Isolation and characterization of a semen-specific protein from human seminal plasma: A potential new marker for semen identification. J Forensic Sci 1978; 23: 106– 115. 10 Brawer MK, Rennels MA, Nagle RB, et al: Serum prostate specific antigen and prostate pathology in men having simple prostatectomy. Am J Clin Pathol 1989; 92: 760– 764. 11 Brawer MK, Bostwick DM, Peehl DM, et al: Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res 1985; 45: 3663– 3667. 12 Bostwick DM, Brawer MK: Prostatic intraepithelial neoplasia and early invasion in prostate cancer. Cancer 1987; 59: 788– 794. 13 Bigler SA, Brown M, Deering RE, Brawer MK: Immunohistochemistry of type VII collagen in human prostatic tissue. J Urol 1994; 151 (Suppl): 277A. 14 Fuchs ME, Brawer MK, Rennels MA, Nagle RB: The relationship of basement membrane to histologic grade of human prostatic carcinoma. Modern Path 1989; 2: 105– 111. 15 Catalona WJ, Smith DS, Ratliff TL, et al: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156– 1161. 16 Catalona WJ, Smith DS, Ratliff TL, Basler JW: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270: 948– 954. 17 Brawer MK, Chetner MP, Beatie J, et al: Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992 147: 841– 845. 18 Catalona WJ, Richie JP, Ahmann FR, et al: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151: 1283– 1290. 19 Brawer MK, Lange PH: PSA in the screening, staging and follow up of early-stage prostate cancer: A review of recent developments. World J Urol 1989; 7: 7– 11. 20 Brawer MK, Beattie J, Wener MH, et al: Screening for prostatic carcinoma with prostate specific antigen: Results of the second year. J Urol 1993; 150: 106– 109. 21 Brawer MK, Beatie J, Wener MH: PSA as the initial test in prostate carcinoma screening: Results of the third year. J Urol 1993; 149 (Suppl): 299A. 22 Kinne DW, Kopans DB: Physical examination and mammography in the diagnosis of breast disease, in JR Harris et al (ed): Breast Disease. Philadelphia, JB Lippincott Company, 1987. 23 Moskowitz M: Cost-benefit determinations in screening mammography. Cancer 1987; 60 (Suppl): 1680– 1683. 24 Babaian RJ, Camps JL: The role of prostate-specific antigen as part of the diagnostic triad and as a guide when to perform a biopsy. Cancer 1991; 68: 2060– 2063. 25 Bazinet M, Meshref AW, Trudel C, et al: Prospective evaluation of prostate-specific antigen density and systematic biopsies for early detection of prostatic carcinoma. Urology 1994; 43: 44– 52. 26 Cooner WH, Mosley BR, Rutherford CL Jr: Clinical application of transrectal ultrasonography and prostate specific antigen in the search for prostate cancer. J Urol 1988; 139: 758– 761. 27 Cooner WH, Mosley BR, Rutherford CL Jr, et al: Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 1990; 143: 1146– 1154. 28 Mettlin C, Lee F, Drago J, et al: The American Cancer Society National Prostate Cancer Detection Project: Findings on the detection of early prostate cancer in 2425 men. Cancer 1991; 67: 2949– 2958. 29 Rommel FM, Augusta VE, Breslin JA, et al: The use of prostate specific antigen and prostate specific antigen density in the diagnosis of prostate cancer in a community based urology practice. J Urol 1994; 151: 88– 93. 30 Ellis WJ, Chetner MP, Preston SD, Brawer MK: Diagnosis of prostatic carcinoma: The yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasound. J Urol 1994; 152: 1520– 1525. 31 Mettlin C, Jones G, Averette H, et al: Defining and updating the ACS guidelines for the cancer related check-up: Prostate and endometrial cancer. CA Cancer J Clin 1993; 43: 42– 46. 32 Brawer MK, Schifman RB, Ahmann FR, et al: The effect of digital rectal examination on serum levels of prostate specific antigen. Arch Pathol Lab Med 1988; 112: 1110– 1112. 33 Crawford ED, Schutz M, Clejan S, et al: The effect of digital rectal examination on prostate specific antigen. J Urol 1991; 145: 398A. 34 Yuan JJ, Catalona WJ: Effect of digital rectal examination, prostate massage, transrectal ultrasonography and needle biopsy of the prostate on serum prostate specific antigen levels. J Urol 1991; 145: 213A. 35 Carter HB, Morrell CH, Pearson JD, et al: Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 1992; 52: 3323– 3328. 36 Pearson JD, Carter HB: Natural history of changes in prostate specific antigen in early stage prostate cancer. J Urol 1994; 152: 1743– 1748. 37 Schmid HP, McNeal JE, Stamey TA: Observations on the doubling time of prostate cancer: The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993; 71: 2031– 2040. 38 Porter JR, Hayward R, Brawer MK: The significance of short-term PSA change in men undergoing ultrasound-guided prostate biopsy. J Urol 1994; 151 (Suppl): 293A. 39 Littrup PJ, Kane RA, Mettlin CJ, et al: Cost-effective prostate cancer detection. Cancer 1994; 74: 3146– 3158. 40 Komatsu K, Wehner N, Prestigiacomo AF, et al: Variation of serum prostate specific antigen in 814 men from a screening population: Intra-individual assay variation is greater than the repeat assay variation. J Urol 1994; 151 (Suppl): 401A. 41 Benson MC, Whang IS, Olsson CA, et al: The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992; 147: 817– 821. 42 Benson MC, Whang IS, Pantuck A, et al: Prostate specific antigen density: A means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992; 147: 815– 816. 43 Babaian RJ, Fritsche HA, Evans RB: PSA and prostate gland volume: Correlation and clinical application. J Clin Lab 1990; 4: 135– 137. 44 Brawer MK, Aramburu EAG, Chen GL, et al: The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma. J Urol 1993; 150: 369– 373. 45 Stamey TA: Making the most out of six systematic sextant biopsies. Urology 1995; 45: 2– 12. 46 Bazinet M: Personal communication. 1994. 47 Rommel FM: Personal communication. 1994. 48 Mettlin C, Littrup PJ, Kane RA, et al: Relative sensitivity and specificity of serum prostate specific antigen level compared with age-referenced PSA, PSA density, and PSA change. Cancer 1994; 74: 1615– 1620. 49 Myrtle J, Klimley P, Ivor L, Bruni J: Clinical utility of prostate specific antigen (PSA) in the management of prostate cancer. Advances in Cancer Diagnostics. 1986. 50 Oesterling JE, Jacobsen SJ, Chute CG, et al: Serum prostate-specific antigen in a community-based population of healthy men. JAMA 1993; 270: 860– 864. 51 Dalkin BL, Ahmann FR, Kopp JB: Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. J Urol 1993; 150: 1837– 1839. 52 Mettlin C, Murphy GP, Lee F, et al: Characteristics of prostate cancer detected in the American Cancer Society-National Prostate Cancer Detection Project. J Urol 1994; 152: 1737– 1740. 53 Petteway J, Brawer MK: Age specific vs. 4.0 ng/ml as a PSA cutoff in the screening population: Impact on cancer detection. J Urol 1995; 153 (Suppl): 465A. 54 Catalona WJ, Hudson MA, Scardino PT, et al: Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: Receiver operating characteristic curves. J Urol 1994; 151 (Suppl): 449A. 55 Christensson A, Bjork T, Nilsson O, et al: Serum prostate specific antigen complexed to α1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993; 150: 100– 105. 56 Lilja H: Significance of different molecular forms of serum PSA: The free, noncomplexed form of PSA versus that complexed to α1-antichymotrypsin. Urol Clin N Am 1993; 20: 681– 686. 57 Stenman U, Leinonen J, Alfthan H, et al: A complex between PSA and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222– 226. 58 Lilja H, Christensson A, Dahlen U, et al: Prostate-specific antigen in serum occurs predominantly in complex with α1-antichymotrypsin. Clin Chem 1991; 37: 1618– 1625. 59 Lilja H, Bjork T, Abrahamsson P, et al: Improved separation between normals, BPH and carcinoma of the prostate by measuring free, complexed and total concentrations of prostate specific antigen. J Urol 1994; 151 (Suppl): 400A. 60 Stamey TA, Chen Z, Prestigiacomo A: Serum prostate specific antigen binding αl-antichymotrypsin: Influence of cancer volume, location and therapeutic selection of resistant clones. J Urol 1994; 152: 1510– 1514. 61 Brawer MK, Wener MH, Daum PR, Close B: Method to method variation in assays for PSA. J Urol 1994; 151 (Suppl): 450A. 62 Brawer MK, Daum P, Petteway JC, Wener MH: Assay variability in serum PSA determination. Prostate 1995. in press. 63 Murphy GP: The second Stanford conference on international standardization of PSA assays. Cancer 1995; 75: 122– 128. 64 Ellis WJ, Brawer MK: Repeat prostate needle biopsy: Who needs it? J Urol 1995. in press. 65 Feightner JW: The early detection and treatment of prostate cancer: The perspective of the Canadian Task Force on the periodic health examination. J Urol 1994; 152: 1682– 1684. 66 Woolf SH: Public health perspective: The health policy implications of screening for prostate cancer. J Urol 1994; 152: 1685– 1688. 67 Gohagan JK, Prorok PC, Kramer BS, Cornett JE: Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial of the National Cancer Institute. J Urol 1994; 152: 1905– 1909. 68 Wilt TJ, Brawer MK: The prostate cancer intervention versus observation trial: A randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. J Urol 1994; 152: 1910– 1914. Citing Literature Volume45, Issue3May/June 1995Pages 148-164 ReferencesRelatedInformation" @default.
• W2023241724 created "2016-06-24" @default.
• W2023241724 creator A5049251419 @default.
• W2023241724 date "1995-05-01" @default.
• W2023241724 modified "2023-10-17" @default.
• W2023241724 title "How to use prostate-specific antigen in the early detection or screening for prostatic carcinoma" @default.
• W2023241724 cites W12660874 @default.
• W2023241724 cites W166500613 @default.
• W2023241724 cites W1668302104 @default.
• W2023241724 cites W1845134010 @default.
• W2023241724 cites W1847856759 @default.
• W2023241724 cites W195741252 @default.
• W2023241724 cites W1969762458 @default.
• W2023241724 cites W1970845670 @default.
• W2023241724 cites W1975145253 @default.
• W2023241724 cites W1975462140 @default.
• W2023241724 cites W1985785474 @default.
• W2023241724 cites W2002538042 @default.
• W2023241724 cites W2029089946 @default.
• W2023241724 cites W2032553244 @default.
• W2023241724 cites W2033457037 @default.
• W2023241724 cites W2042123453 @default.
• W2023241724 cites W2051983269 @default.
• W2023241724 cites W2053822295 @default.
• W2023241724 cites W2061879006 @default.
• W2023241724 cites W2064191137 @default.
• W2023241724 cites W2070303233 @default.
• W2023241724 cites W2084197013 @default.
• W2023241724 cites W2085887715 @default.
• W2023241724 cites W2088686351 @default.
• W2023241724 cites W2105397433 @default.
• W2023241724 cites W2147530910 @default.
• W2023241724 cites W2159280763 @default.
• W2023241724 cites W2162461452 @default.
• W2023241724 cites W2165936524 @default.
• W2023241724 cites W2295904834 @default.
• W2023241724 cites W2330292521 @default.
• W2023241724 cites W2335679869 @default.
• W2023241724 cites W2394905488 @default.
• W2023241724 cites W2395925941 @default.
• W2023241724 cites W2396094426 @default.
• W2023241724 cites W2406847553 @default.
• W2023241724 cites W2407415728 @default.
• W2023241724 cites W2408965256 @default.
• W2023241724 cites W2412124017 @default.
• W2023241724 cites W2412969837 @default.
• W2023241724 cites W2414200218 @default.
• W2023241724 cites W2415244491 @default.
• W2023241724 cites W2472758901 @default.
• W2023241724 cites W2863643 @default.
• W2023241724 cites W2911471049 @default.
• W2023241724 cites W333212257 @default.
• W2023241724 cites W38427941 @default.
• W2023241724 cites W65565690 @default.
• W2023241724 cites W78998479 @default.
• W2023241724 cites W79277627 @default.
• W2023241724 cites W96058809 @default.
• W2023241724 cites W2042772331 @default.
• W2023241724 cites W2209826608 @default.
• W2023241724 doi "https://doi.org/10.3322/canjclin.45.3.148" @default.
• W2023241724 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7538043" @default.
• W2023241724 hasPublicationYear "1995" @default.
• W2023241724 type Work @default.
• W2023241724 sameAs 2023241724 @default.
• W2023241724 citedByCount "36" @default.
• W2023241724 countsByYear W20232417242012 @default.
• W2023241724 countsByYear W20232417242013 @default.
• W2023241724 countsByYear W20232417242014 @default.
• W2023241724 countsByYear W20232417242021 @default.
• W2023241724 crossrefType "journal-article" @default.
• W2023241724 hasAuthorship W2023241724A5049251419 @default.
• W2023241724 hasBestOaLocation W20232417241 @default.
• W2023241724 hasConcept C121608353 @default.
• W2023241724 hasConcept C126322002 @default.
• W2023241724 hasConcept C126894567 @default.
• W2023241724 hasConcept C143998085 @default.
• W2023241724 hasConcept C147483822 @default.
• W2023241724 hasConcept C203014093 @default.
• W2023241724 hasConcept C2776235491 @default.
• W2023241724 hasConcept C2777546739 @default.
• W2023241724 hasConcept C2781406297 @default.
• W2023241724 hasConcept C2993388676 @default.
• W2023241724 hasConcept C71924100 @default.
• W2023241724 hasConceptScore W2023241724C121608353 @default.
• W2023241724 hasConceptScore W2023241724C126322002 @default.
• W2023241724 hasConceptScore W2023241724C126894567 @default.
• W2023241724 hasConceptScore W2023241724C143998085 @default.
• W2023241724 hasConceptScore W2023241724C147483822 @default.
• W2023241724 hasConceptScore W2023241724C203014093 @default.
• W2023241724 hasConceptScore W2023241724C2776235491 @default.
• W2023241724 hasConceptScore W2023241724C2777546739 @default.
• W2023241724 hasConceptScore W2023241724C2781406297 @default.
• W2023241724 hasConceptScore W2023241724C2993388676 @default.
• W2023241724 hasConceptScore W2023241724C71924100 @default.
• W2023241724 hasIssue "3" @default.
• W2023241724 hasLocation W20232417241 @default.
• W2023241724 hasLocation W20232417242 @default.
• W2023241724 hasOpenAccess W2023241724 @default.

• next